Adipocytokines and sex hormone disorders in patients with chronic renal failure (CRF)

Endokrynologia Polska

Volumn 63, Issue 2, 2012, Pages 148-155

  Niemczyk, Stanisław ^a   Romejko Ciepielewska, Katarzyna ^a   Niemczyk, Longin ^b  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Adipocytokines; Adiponectin; Leptin; Renal failure; Resistin; Sex hormones; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; FOLLITROPIN; INSULIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROGESTERONE; RESISTIN; SEX HORMONE;

ANOREXIA; ANORGASMIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CYTOKINE RELEASE; DISEASE ASSOCIATION; FEMALE INFERTILITY; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPOGONADISM; LIBIDO DISORDER; MALE INFERTILITY; MENSTRUATION DISORDER; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; WASTING SYNDROME;

ADIPOKINES; BIOLOGICAL MARKERS; FEMALE; GONADAL STEROID HORMONES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE;

EID: 84861142062     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432. (Pubitemid 24365442)
2. Bado A, Levasseur S, Attoub S et al. The stomach is a source of leptin. Nature 1998; 394: 790-793. (Pubitemid 28391644)
3. Morash B, Li A, Murphy P et al. Leptin gene expression in the brain and pituitary gland. Endocrinology 1999; 140: 5995-5998. (Pubitemid 30645391)
4. Wang J, Liu R, Hawkins M et al. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 1998; 393: 684-688. (Pubitemid 28289657)
5. Masuzaki H, Ogawa Y, Sagawa N et al. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med 1997; 3: 1029-1033. (Pubitemid 27391961)
6. Tsiotra PC, Pappa V, Raphis SA et al. Expression of the long and short leptin receptor isoforms in peripheral blood mononuclear cells: implications for leptin's actions. Metabolism 2000; 49: 1537-1541. (Pubitemid 32010839)
7. Wallace AM. Measurement of leptin and leptin binding in the humans circulation. Ann Clin Biochem 2000; 37: 244-252. (Pubitemid 30242754)
8. Marioka T, Asilmaz E, Hu J et al. Disruption of leptin receptor's expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest 2007; 117: 2860-2868. (Pubitemid 47529616)
9. Margetic S, Gazzola C, Pegg GG et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26: 1407-1433. (Pubitemid 36007818)
10. Halleux CM, Servais I, Reul BA et al. Multihormonal control of ob gene expression and leptin secretion from cultured human visceral adipose tissue: increased responsiveness to glucocorticoids in obesity. J Clin Endocrinol Metab 1998; 83: 902-910. (Pubitemid 28496464)
11. Wellen KE, Hotamisligil GS. Inflammation, stress and diabetes. J Clin Invest 2005; 115: 1111-1119.
12. Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin in obesity, T cell hyporesponsiveness and neroendocrine/metabolic dysfunction in human congenital leptin deficiency. J Clin Invest 2002; 110: 1093-1103. (Pubitemid 35215890)
13. Ahima RS, Prabakaran P, Mantzoros C et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250-252. (Pubitemid 26251358)
14. Chan JL, Heist K, De Paoli AM et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 2003; 111: 1409-1421. (Pubitemid 36554712)
15. Lord GM, Matarese G, Howard JK et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosupression. Nature 1988; 394: 897-901.
16. Meyer C, Robson D, Rackovsky N et al. Role of the kidney in human leptin metabolism. Am J Physiol 1997; 273: 903-907.
17. Considine RV, Sinha MK, Heiman HL et al. Serum immunoreactive - leptin concentrations in normal - weight and obese humans. N Engl J Med 1996; 334: 292-295. (Pubitemid 26033933)
18. Diez JJ, Iglesias P, Codoceo R et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005; 62: 242-249. (Pubitemid 40203922)
19. Menon V, Wang X, Greene T et al. Factors associated with serum leptin in patients with chronic kidney disease. Clin Nephrol 2004; 61: 163-169. (Pubitemid 38396906)
20. Saladin R, De Vos P, Guerre-Millo M et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377: 527-529.
21. Scholze A, Rattensperger D, Zidek W et al. Low serum leptin predicts mortality in patients with kidney disease stage 5. Obesity 2005; 15: 1617-1622.
22. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808. (Pubitemid 36315558)
23. Zoccali C, Tripepi G, Cambareri F et al. Adipose tissue cytokines, insulin sensitivity, inflammation and cardiovascular outcomes in end-stage renal disease patients. J Ren Nutr 2005; 15: 125-130. (Pubitemid 40093696)
24. Cheung CC, Clifton DK, Steiner RA. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 1997; 138: 4489-4492. (Pubitemid 27408500)
25. Schwarz MW, Seeley RJ, Woods SC et al. Leptin increases hypothalamic proopiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 1997; 46: 2119-2123. (Pubitemid 27512108)
26. Cioffi JA, Shafer AW, Zupancic TJ et al. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nat Med 1996; 2: 585-589. (Pubitemid 26151519)
27. Axelsson J, Qureshi AR, Heimburger O et al. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis 2005; 46: 628-634. (Pubitemid 41383940)
28. Atamer A, Alisir Ecder S, Akkus Z et al. Relationship between leptin, insulin resistence, insulin-like growth factor-1 and insulin-like growth factor binding protein 3 in patients with chronic kidney disease. J Int Med Res 2008; 36: 522-528. (Pubitemid 351833602)
29. Halleux CM, Takahashi M, Delporte ML et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001; 288: 1102-1107. (Pubitemid 33131713)
30. Kissebah AM, Sonnenberg GE, Mykelbust J et al. Quantitive trait loci on chromosomem 3 and 17 influence pheotypes of metabolic syndrome. Proc Natl Acad Sci USA 2000; 97: 14 478-14 483.
31. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451. (Pubitemid 40686653)
32. Pineiro R, Iglesias MJ, Gallego R et al. Adiponectin is synthesised and secreted by human and murine cardiomyocytes. FEBS Lett 2005; 579: 5163-5169. (Pubitemid 41318086)
33. Delaigle AM, Jonas JC, Bauche IB et al. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 2004; 145: 5589-5597.
34. Buemann B, Sorensen TJ, Pedersen O et al. Lower body mass as an independent marker of insulin sensitivity - the role of adiponectin. Int J Obes (Lond) 2005; 29: 624-631. (Pubitemid 40769484)
35. Pajvani VB, Du X, Combs TP et al. Structure-function studies of the adipocyte secreted hormone Acrp 30/adiponectin. Implication for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085. (Pubitemid 36800387)
36. Whitehead JP, Richards AA, Hickman IJ et al. Adiponectin-a key adipose in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-280.
37. Gavrila A, Peng CK, Chan JL et al. Diurnal ultradian dynamice of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003; 88: 2838-2843. (Pubitemid 36724465)
38. Kumada A, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89. (Pubitemid 36091630)
39. Pilz S, Havejsi R, Moller S et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab 2005; 90: 4792-4796. (Pubitemid 41159373)
40. Stefan N, Vozarova B, Funahashi T et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedens a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-1888. (Pubitemid 34564302)
41. Ouchi N, Kihara S, Funahashi T et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-674. (Pubitemid 36222590)
42. Wolf AM, Wolf D, Rumpold H et al. Adiponectin induces the anti-inflammatory cytokines Il-10 and Il-1RA in human leukocytem. Biochem Biophys Res Commun 2004; 323: 630-635. (Pubitemid 39221142)
43. Koshimura J, Fujita M, Narita T et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 2004; 316: 165-169. (Pubitemid 38299140)
44. Shoji T, Shinohara K, Matsuda S et al. Altered relationship between body fat plasma adiponectin in end-stage renal disease. Metabolism 2005; 54: 330-334. (Pubitemid 40250092)
45. Zoccali C, Mallamaci F, Panuccio V et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int 2003; 63: 98-102.
46. Stenvinkel P, Marchlewska A, Pecoits-Filho R et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 2004; 65: 274-281. (Pubitemid 38037514)
47. Zoccali F, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141. (Pubitemid 34042020)
48. Huang JW, Yen CJ, Chiang HW et al. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004; 43: 1047-1055.
49. Mak RH, Cheung W. Adipokines and Gut Hormones in end-stage renal disease. Perit Dial Int 2007; 27: 298-302.
50. Díez JJ, Iglesias P, Fernández-Reyes MJ et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005; 62: 242-249. (Pubitemid 40203922)
51. Shen YY, Charlesworth JJ, Kelly JJ et al. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 2007; 22: 171-178. (Pubitemid 46050342)
52. Qi Y, Takahashi N, Hilman SM et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529. (Pubitemid 38667912)
53. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312. (Pubitemid 32151228)
54. Banarjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med 2003; 81: 218-226. (Pubitemid 36578920)
55. Savage DB, Sewter CP, Klenk ES et al. Resistin/FIZZ3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202. (Pubitemid 33641901)
56. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455. (Pubitemid 37452753)
57. Youn BS, Yu KY, Park HJ et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 150-156. (Pubitemid 38183874)
58. Satoh H, Nguyen MT, Miles PD et al. Adenovirus-mediated chronic "hyperresistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest 2004; 114: 224-231. (Pubitemid 39071627)
59. Lee JH, Chan JL, Yinnakouris N et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-4856. (Pubitemid 37357535)
60. Janke J, Eugeli S, Gorzelniak K et al. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002; 10: 1-5. (Pubitemid 135686624)
61. Shetty GK, Economides PA, Horton ES et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers and cardiovascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457. (Pubitemid 39281400)
62. Kawanami D, Maemura K, Takeda N et al. Direct reciprocal effects of resistin and adiponectinon vascular endothelial cells: a new insight into adipocytokine-endothelial cell interaction. Biochem Biophys Res Commun 2004; 314: 415-419. (Pubitemid 38084733)
63. Senolt LA, Housa D, Vernerová Z et al. Resistin in rheumathoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007; 66: 458-463. (Pubitemid 46580464)
64. Reilly MP, Lehrke M, Wolfe ML et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939. (Pubitemid 40279897)
65. Axelsson J, Bergsten A, Qureshi AR et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69: 596-604. (Pubitemid 43164455)
66. Kielstein JT, Becker B, Graf S et al. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003; 42: 62-66. (Pubitemid 36807655)
67. Filippidis G, Liakapoulos V, Mertens PR et al. Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purif 2005; 23: 421-428. (Pubitemid 41816068)
68. Axelsson J, Bergsten A, Qureshi AR et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69: 596-604. (Pubitemid 43164455)
69. Dahl TB, Yndestad A, Skjelland M et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-980. (Pubitemid 46328290)
70. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: 64-73.
71. Moschen AR, Kaser A, Erich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758. (Pubitemid 46154646)
72. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects by insulin. Science 2005; 307: 426-430. (Pubitemid 40139988)
73. Jia SH, Li Y, Parodo J et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-1327. (Pubitemid 39069931)
74. Kim SR, Bae SK, Choi KS et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 2007; 357: 150-156.
75. Otero M, Lago R, Gomez R et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-1201. (Pubitemid 44277396)
76. Koczan D, Guthke R, Thiesen HJ et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005; 15: 251-257. (Pubitemid 41020851)
77. Zhong M, Tan HW, Gong HP et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol 2008; 69: 878-884.
78. Chen MP, Chung FM, Chang DM et al. Elevated plasma level of visfatin/ pre-B cell colony enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299.
79. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875. (Pubitemid 44923689)
80. Erten Y, Ebinç FA, Emin H et al. The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 2008; 30: 617-623.
81. Nüsken KD, Petrash M, Rauch M et al. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterole. Nephrol Dial Transplant 2009; 24: 2832-2838.
82. Kato A, Odamaki H, Ishida J et al. Relationship between serum pre-B cell colonyenhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol 2009; 29: 31-35.
83. Axelsson J, Witasp A, Carrero JJ.: Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-244. (Pubitemid 46178402)
84. Palmer BF. Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. Adv Renal Rep Therapy 2003; 10: 48-60. (Pubitemid 36278330)
85. Holley JL, Schmidt RJ, Bender FM et al. Gynecologic and reproductive issues in women on dialysis. Am J Kidney Dis 1997; 29: 685-690. (Pubitemid 27209669)
86. Zingraff J, Jungers P, Pélissier C et al. Pituitary and ovarian dysfunctions in women on haemodialysis. Nephron 1982; 30: 149-153. (Pubitemid 12146996)
87. Lim VS, Henriques C, Sievertsen G et al. Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation. Ann Intern Med 1980; 93: 21-27. (Pubitemid 10071995)
88. Diemont WL, Vruggink PA, Meuleman EJ et al. Sexual dysfunction after renal replacement therapy. Am J Kidney Dis 2000; 35: 845-851. (Pubitemid 30238196)
89. Matuszkiewisz-Rowińska J, Skórzewska K, Radowicki S et al. Endometrial morphology and pituitary - gonadal axis dysfunction in women of reproductive age undergoing haemodialysis - a multicentre study. Nephrol Dial Transplant 2004; 19: 2074-2077. (Pubitemid 39139640)
90. Ginsburg ES, Owen WF. Reproductive endocrinology and pregnancy in women on hemodialysis. Semin Dial 1993; 6: 105-116.
91. Yu W, Kimura M, Walczewska A et al. Role of leptin in hypothalamic - pituitary function. Proc Natl Acad Sci USA 1997; 94: 1023-1028. (Pubitemid 27074441)
92. Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10: 1381-1388. (Pubitemid 29247005)
93. Sievertsen GD, Lim VS, Nakawatase C et al. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab 1980; 50: 846-852. (Pubitemid 10016437)
94. Gómez F, De La Cueva R, Wauters JP et al. Endocrine abnormalities in patients undergoing long - term hemodialysis. The role of prolactin. Am J Med 1980; 68: 522-530. (Pubitemid 10141817)
95. Hou S. Pregnancy in women with chronic renal disease. N Engl J Med 1985; 312: 836-839. (Pubitemid 15104777)
96. Ghazizadeh S, Lessan-Pezeshki M, Mahdavi M et al. Menstrual problems among kidney transplant recipients. Transplant Proc 2003; 35: 2720-2721. (Pubitemid 37378136)
97. Schaefer R, Kokot F, Wernze H et al. Improved sexual function in hemodialysis patients on recombinant erythropoietin: a possible role of prolactin. Clin Nephrol 1989; 31: 1-5. (Pubitemid 19033527)
98. Toorians AW, Janssen E, Laan E et al. Chronic renal failure and sexual functioning: Clinical status versus objectively assessed sexual response. Nephrol Dial Transplant 1997; 12: 2654-2663. (Pubitemid 27520690)
99. Prem AR, Punekar SV, Kalpana M et al. Male reproductive function in uremia: Efficacy of haemodialysis and renal transplantation. Br J Urol 1996; 78: 635-638. (Pubitemid 27407837)
100. Holdsworth S, Atkins RC, De Kretser DM. The pituitary - testicular axis in men with chronic renal failure. N Engl J Med 1977; 296: 1245-1249. (Pubitemid 8123910)
101. Dunkel L, Raivio T, Laine J et al. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int 1997; 51: 777-784. (Pubitemid 27157962)
102. De Vries CP, Gooren LJ, Oe PL. Haemodialysis and testicular function. Int J Androl 1984; 7: 97-103. (Pubitemid 14131811)
103. Palmer BF. Outcomes associated with hypogonadism in men with chronic kidney disease. Adv Chronic Kidney Dis 2004; 11: 342-347. (Pubitemid 39361494)
104. Mendoza C, Carreras A, Ruiz E et al. Hypothalamo-hypophyseo-gonadal axis in individuals with chronic renal insufficiency subjected to hemodialysis. Rev Esp Fisiol 1985; 41: 443-446.
105. Phocas I, Sarandakou A, Rizos D et al. Serum α-immunoreactive inhibin in males with renal failure, under haemodialysis and after successful renal transplantation. Andrologia 1995; 27: 253-258.
106. Lim V, Fang VS. Restoration of plasma testosterone levels in uremic men with clomiphene citrate. J Clin Endocrinol Metab 1976; 43: 1370-1377. (Pubitemid 8011416)
107. Le Roith D, Danovitz G, Trestian S et al. Dissociation of pituitary glycoprotein response to releasing hormones in chronic renal failure. Acta Endocrinol (Copenh) 1980; 93: 277-282. (Pubitemid 10135435)
108. Gomez F, De La Cueva R, Wauters JP et al. Endocrine abnormalities in patients undergoing long-term hemodialysis: the role of prolactin. Am J Med 1980; 68: 522-530. (Pubitemid 10141817)
109. Hochstetler LA, Flanigan MJ, Lim VS. Abnormal endocrine tests in a hemodialysis patient. J Am Soc Nephrol 1994; 4: 1754-1759.
110. Caticha O, Norato DYJ, Tambascia MA et al. Total body zinc depletion and its relationship to the development of hyperprolactinemia in chronic renal insufficiency. J Clin Endocrinol Invest 1996; 19: 441-448. (Pubitemid 126449225)